Pharma Mar, S.A.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
E8075H159
SEDOL
BMW2GT8
CIK
N/A
pharmamar.com
LEI:
©
FIGI: BBG000F3LRQ5
PHM
Pharma Mar, S.A.
GICS: 35201010 · Sector: Consumer Goods - Pharmacy Products and Biotechnology · Sub-Sector: -
NAME
Pharma Mar, S.A.
ISIN
ES0169501022
TICKER
PHM
MIC
XMAD
REUTERS
PHM.MC
BLOOMBERG
PHM SM
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
TradingView ActivTrader MT4 MT5
In this section you will find transaction histories for short sales.
ai
NALIZER
The overview shows all positions and their last reported status. Please note that when reducing positions, falling below the 0.50% limit means that the mandatory reporting obligations no longer have to be applied. As a rule, it can be assumed that the positions have been completely reduced following a longer period of inactivity. Positions < 0.50% are therefore only of limited significance.
Date Position Holder Position # Action
01.10.2024 Citadel Advisors LLC 0,49% 28
24.07.2024 Arrowstreet Capital, Limited Partnership 0,49% 12
18.03.2022 AHL PARTNERS LLP 0,48% 14
28.02.2022 D. E. Shaw & Co., L.P. 0,47% 2
28.07.2021 Consonance Capital 0,48% 6
22.01.2021 WorldQuant, LLC 0,47% 14
11.12.2020 Great Point Partners, LLC 0,42% 4
03.12.2020 Point72 Asset Management, L.P. 0,42% 2
08.05.2020 PDT Partners, LLC 0,49% 6
20.03.2020 Winton Capital Management 0,45% 2
27.12.2019 Marshall Wace LLP 0,47% 20
27.11.2017 Wellington Managment Company, LLP 0,49% 10
SHORT SELLING RADAR (“SSR”)
SSR - First TIMER
SSR - DASHBOARD
HEDGE FUND ACTIVITY TRACKER
SSR Weight WATCHER
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements
The information provided in this area is compiled with care and prepared and processed in complex technical process steps. Quality assurance is an integral part of the methods and procedures used. A plausibility check is carried out to the extent that the source data allows. Before further use, especially in the course of any investment decisions, we recommend consulting at least one second independent source for validation.